FORT LAUDERDALE, FL–(Marketwire – March 2, 2010) –  OmniComm Systems, Inc. (OTCBB: OMCM), a global provider of eClinical solutions, announced today that it was selected by a leading pharmaceutical company to provide OmniComm’s flagship EDC Solution, TrialMasterT, for a Phase III study of a drug to test a central nervous system disorder. The contract is for in excess of $200,000 and total revenue generated from this customer exceeds $750,000 over the last six months. 

Further information:

Article source

Related posts:

1. OmniComm Selected EDC “Vendor of Choice” by Leading East Coast Based Biotech for Phase II Central Nervous System Study
2. Merck Reports Results of Phase III Study of Investigational Oral Allergy Immunotherapy Tablet (AIT) in Patients Ages 5-17 with Grass Pollen Allergy
3. Diamyd Medical: Diamyd US Phase III Study Well Under Way
4. Avastin Phase III Study Shows Positive Results In Women With Advanced Ovarian Cancer
5. Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer